ClinicalTrials.gg
CompletedNCT05604794Updated Mar 20, 2024Results posted

A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health

A Phase 4 interventional study of Ketamine-Assisted Psychotherapy (KAP) in Depression, Anxiety and Post Traumatic Stress Disorder, sponsored by Field Trip Health. Completed at 11 sites in 2 countries. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-03-20.

Sponsored by Field Trip Health · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 6 months after the study started (first participant enrolled Mar 2020, registered Oct 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,806
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,713 studies in Depression with a site in United States — 582 open to participants now, 720 under way, 30 of them phase 3. Depression · United States.

Enrollment
68th of 3,320
1,806 · median 72
Started
2020
with 154 others
Phase 4
265 of 3,713
19 open now
Registered
2,895th of 3,713
by date

Among the 3,713 studies in Depression with a site in United States, this one is the 68th largest by enrollment of the 3,320 interventional ones that give a count, is one of 155 that started in 2020, is one of 265 in phase 4, and was the 2,895th registered.

Depression

8,595 studies on the registry are indexed under Depression; 1,732 are open to participants now.

Browse Depression studies →

Open to participants now

582 of the 3,713 studies in Depression with a site in United States are open now. Recruiting first, the newest first:

577 more — sign in →

All 582 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,094 Depression studies recruiting now, 472 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 314 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,713 studies in Depression with a site in United States, or all of them as a file.
02

Study summary

Ketamine-Assisted Psychotherapy (KAP) is a relatively new approach for the treatment of mental health issues, which involves the combination of ketamine, a dissociative anaesthetic with psychedelic properties, and psychotherapy to promote emotional wellbeing. In this study, we investigated the effectiveness of KAP in adult patients coping with mental health. We predicted that clients would experience lasting reductions in psychological distress over time, such as depression, anxiety, and post traumatic stress, that would be detectable up to 6 months after treatment. The results of this study may provide evidence of sustained real-world effects of Ketamine-Assisted Psychotherapy, of interest to patients, clinicians, researchers, and policymakers.

Read the detailed description

Background: Ketamine-Assisted Psychotherapy (KAP) has shown positive effects within clinical trial settings and over short-term follow-ups, but sustained effects in real-world treatment settings remain unclear. In this study, we investigated the effectiveness of KAP in adult patients coping with mental health issues. We hypothesized that there would be significant reductions in psychological distress over time.

Objective: To examine treatment effects at 1, 3, and 6 months relative to baseline on depression, anxiety, and post traumatic stress outcomes.

Design: A retrospective intervention-only effectiveness trial.

Setting: KAP was administered across 11 Field Trip Health clinics in North America. Intervention: KAP consisting of 4-6 guided ketamine sessions with psychotherapy-only visits after dose 1 and 2 and then after every 2 subsequent doses.

Outcomes: Self-reported measures of symptoms of depression, anxiety, and post traumatic stress at 1, 3, and 6 months.

Statistical Analysis: Analyses were by intention to treat. Main analysis was a mixed linear model or growth curve model to estimate change over time per outcome, yielding estimates of mean changes at each endpoint relative to baseline. Secondary analyses included evaluating case reductions (identified by cut-off values) and minimal clinically important differences (MCIDs) at each endpoint relative to baseline.

Significance: This study may provide evidence of sustained real-world effects of Ketamine-Assisted Psychotherapy, of interest to patients, clinicians, researchers, and policymakers.

03

Conditions studied

  • Depression
  • Anxiety
  • Post Traumatic Stress Disorder

Keywords

  • ketamine
  • psychotherapy
  • mental health
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Over the age of 18
  • Should be psychologically and medically cleared by a psychiatrist, family physician, or treatment team
  • Diagnosed with Major Depressive Disorder (MDD), Bipolar Depression, Generalized Anxiety Disorder, Obsessive Compulsive Disorder (OCD), and Eating Disorder by a licensed healthcare practitioner (including Field Trip Consultants)
  • A significant history of trauma and/or formal diagnosis of PTSD as per the 5 (DSM 5)
  • Individuals who have received Electroconvulsive Therapy (ECT) or other neuromodulatory treatments like Transcranial Magnetic Stimulation (TMS)
  • Individuals reporting suicidal ideation may be included, as suicidal ideation is a symptom of a Major Depressive Episode (MDE)

Exclusion criteria

Exclusion Criteria:

  • Individuals who are unable to consent to the treatment
  • Pregnant women and nursing mothers

    --Note that Post Partum Depression (PPD) can be considered on a case-by-case basis in consultation with the National Medical Director.

  • There is a relative (not absolute) for individuals with a (BMI) of above 35. These clients must be given thorough consideration by the medical team.
  • Any individual who has met DSM 5 criteria for a Substance Use Disorder in the past 3 months.

    • Note that patients with alcohol, opioid, benzodiazepine, cocaine, and amphetamine use disorders need to go through detox (for alcohol/benzodiazepines) and be sober for 4 weeks.
    • Note that mild active alcohol, cocaine, and cannabis use can be considered on a case-by-case basis at the comfort level of the treatment team if the client has demonstrated abstaining or significant reduction of use prior to starting treatment.
  • Daily use of moderate to high doses of benzodiazepines
  • Individuals who are experiencing psychotic symptoms as part of an MDE (mood congruent/ mood incongruent)
  • Psychosis: Schizophrenia, Schizoaffective disorder, Bipolar 1 with psychotic features during mania
  • Active Mania: Bipolar 1 (chronic non-disruptive hypomania is an exception at the discretion of the consultant)
  • Borderline Personality Disorder
  • Uncontrolled medical disorders
  • Physical conditions with negative interaction with ketamine (e.g., metabolic blood disorder)
  • Individuals with symptomatic acute brain injury within 90 days of serious injury
  • Individuals diagnosed with moderate to severe sleep apnea
  • Individuals who are unable to identify a person or service to assure their safe transport to home post treatment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,806 participants (actual)

Study arms

  • Experimental
    Clients

    Adult patients coping with symptoms of depression, anxiety, and post traumatic stress

    Combination Product: Ketamine-Assisted Psychotherapy (KAP)

Interventions

  • Combination productKetamine-Assisted Psychotherapy (KAP)

    KAP consisting of 4-6 guided ketamine sessions with psychotherapy-only visits after dose 1 and 2 and then after every 2 subsequent doses.

06

What researchers measure

Primary outcomes

  1. 9-item Patient Health Questionnaire (PHQ-9)

    Self-reported measure of depression, ranging from 0-27. Higher scores are worse.

    Time frame: Change from 3 months compared to baseline

  2. 7-item Generalized Anxiety Disorder Measure (GAD-7)

    Self-reported measure of anxiety, ranging from 0-21. Higher scores are worse.

    Time frame: Change from 3 months compared to baseline

  3. 6-item PTSD Checklist (PCL-6)

    Self-reported measure of post traumatic stress, ranging from 6-30. Higher scores are worse.

    Time frame: Change from 3 months compared to baseline

Secondary outcomes

  1. 9-item Patient Health Questionnaire (PHQ-9)

    Self-reported measure of depression, ranging from 0-27.

    Time frame: Change from 1 month compared to baseline

  2. 9-item Patient Health Questionnaire (PHQ-9)

    Self-reported measure of depression, ranging from 0-27.

    Time frame: Change from 6 months compared to baseline

  3. 7-item Generalized Anxiety Disorder Measure (GAD-7)

    Self-reported measure of anxiety, ranging from 0-21.

    Time frame: Change from 1 month compared to baseline

  4. 7-item Generalized Anxiety Disorder Measure (GAD-7)

    Self-reported measure of anxiety, ranging from 0-21.

    Time frame: Change from 6 months compared to baseline

  5. 6-item PTSD Checklist (PCL-6)

    Self-reported measure of post traumatic stress, ranging from 6-30.

    Time frame: Change from 1 month compared to baseline

  6. 6-item PTSD Checklist (PCL-6)

    Self-reported measure of post traumatic stress, ranging from 6-30.

    Time frame: Change from 6 months compared to baseline

07

Results

Posted May 12, 2023
Limitations and caveats
Based on feedback from the peer review process, this study should be considered a cohort study rather than a trial. The high attrition rate may limit validity of results.

Participant flow

Participant flow — Overall Study
MilestoneClients
Started1806
Completed94
Not completed1712

Outcome measures

Primary9-item Patient Health Questionnaire (PHQ-9)

Self-reported measure of depression, ranging from 0-27. Higher scores are worse.

Time frame:
Change from 3 months compared to baseline
Reported as:
Mean · units on a scale
9-item Patient Health Questionnaire (PHQ-9)
units on a scaleClients
9-item Patient Health Questionnaire (PHQ-9)-3.23 (-3.57 to -2.90)
Primary7-item Generalized Anxiety Disorder Measure (GAD-7)

Self-reported measure of anxiety, ranging from 0-21. Higher scores are worse.

Time frame:
Change from 3 months compared to baseline
Reported as:
Mean · units on a scale
7-item Generalized Anxiety Disorder Measure (GAD-7)
units on a scaleClients
7-item Generalized Anxiety Disorder Measure (GAD-7)-4.80 (-5.17 to -4.44)
Primary6-item PTSD Checklist (PCL-6)

Self-reported measure of post traumatic stress, ranging from 6-30. Higher scores are worse.

Time frame:
Change from 3 months compared to baseline
Reported as:
Mean · units on a scale
6-item PTSD Checklist (PCL-6)
units on a scaleClients
6-item PTSD Checklist (PCL-6)-4.24 (-4.60 to -3.87)
Secondary9-item Patient Health Questionnaire (PHQ-9)

Self-reported measure of depression, ranging from 0-27.

Time frame:
Change from 1 month compared to baseline
Reported as:
Mean · units on a scale
9-item Patient Health Questionnaire (PHQ-9)
units on a scaleClients
9-item Patient Health Questionnaire (PHQ-9)-3.23 (-3.57 to -2.90)
Secondary9-item Patient Health Questionnaire (PHQ-9)

Self-reported measure of depression, ranging from 0-27.

Time frame:
Change from 6 months compared to baseline
Reported as:
Mean · units on a scale
9-item Patient Health Questionnaire (PHQ-9)
units on a scaleClients
9-item Patient Health Questionnaire (PHQ-9)-4.74 (-5.68 to -3.80)
Secondary7-item Generalized Anxiety Disorder Measure (GAD-7)

Self-reported measure of anxiety, ranging from 0-21.

Time frame:
Change from 1 month compared to baseline
Reported as:
Mean · units on a scale
7-item Generalized Anxiety Disorder Measure (GAD-7)
units on a scaleClients
7-item Generalized Anxiety Disorder Measure (GAD-7)-2.65 (-2.95 to -2.34)
Secondary7-item Generalized Anxiety Disorder Measure (GAD-7)

Self-reported measure of anxiety, ranging from 0-21.

Time frame:
Change from 6 months compared to baseline
Reported as:
Mean · units on a scale
7-item Generalized Anxiety Disorder Measure (GAD-7)
units on a scaleClients
7-item Generalized Anxiety Disorder Measure (GAD-7)-4.10 (-5.02 to -3.18)
Secondary6-item PTSD Checklist (PCL-6)

Self-reported measure of post traumatic stress, ranging from 6-30.

Time frame:
Change from 1 month compared to baseline
Reported as:
Mean · units on a scale
6-item PTSD Checklist (PCL-6)
units on a scaleClients
6-item PTSD Checklist (PCL-6)-2.14 (-2.44 to -1.83)
Secondary6-item PTSD Checklist (PCL-6)

Self-reported measure of post traumatic stress, ranging from 6-30.

Time frame:
Change from 6 months compared to baseline
Reported as:
Mean · units on a scale
6-item PTSD Checklist (PCL-6)
units on a scaleClients
6-item PTSD Checklist (PCL-6)-3.44 (-4.38 to -2.50)

Adverse events

Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Clients0/1,806 (0%)0/1,806 (0%)0/1,806 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Clients
Mean42 ± 12
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Clients
Gender — Female948
Gender — Male850
Gender — Non-binary8
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Clients
Race/Ethnicity — White1309
Race/Ethnicity — Other Groups441
Race/Ethnicity — Missing56
Region of Enrollment
Region of Enrollment(Participants)Clients
North America1806
08

Study locations

11 sites
  • LA Centre
    Los Angeles, California 90404, United States
  • San Diego Centre
    San Diego, California 92037, United States
  • Washington DC Centre
    Washington, District of Columbia 20005, United States
  • Atlanta Centre
    Atlanta, Georgia 30316, United States
  • Chicago Centre
    Chicago, Illinois 60654, United States
  • NYC Centre
    New York, New York 10010, United States
  • Houston Centre
    Houston, Texas 77027, United States
  • Seattle Centre
    Seattle, Washington 98109, United States
  • Vancouver Centre
    Vancouver, British Columbia V6J 5B3, Canada
  • Fredericton Centre
    Fredericton, New Brunswick E3B 7E6, Canada
  • Field Trip Health, Toronto Centre
    Toronto, Ontario M5V 2C3, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2020 to primary completion in Jun 2022, 27 months.

Results were first posted in May 2023, 10 months after primary completion.

Of 119 phase 4 interventional studies under Depression, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 59. This study's 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2022
First posted
Nov 3, 2022
StartActual
Mar 13, 2020
Primary completionActual
Jun 16, 2022
CompletionActual
Jun 16, 2022
Results first posted
May 12, 2023
Last update
Mar 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05604794
Lead sponsor
Field Trip Health
Responsible party
Sponsor
First posted
Nov 3, 2022
Start date
Mar 13, 2020
Primary completion
Jun 16, 2022
Completion
Jun 16, 2022
Results posted
May 12, 2023
Last update
Mar 20, 2024

Study contacts

Ryan Yermus, MD
principal investigator · Field Trip Health
Chris Lo, PhD
principal investigator · University of Toronto

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion